Hadji, Peyman
Schweikert, Bernd http://orcid.org/0000-0001-8253-509X
Kloppmann, Edda
Gille, Patrick
Joeres, Lars
Toth, Emese
Möckel, Luis http://orcid.org/0000-0002-1338-8433
Glüer, Claus-C. http://orcid.org/0000-0003-3539-8955
Funding for this research was provided by:
UCB Pharma
Amgen Inc.
Christian-Albrechts-Universität zu Kiel
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Article History
Received: 24 September 2020
Accepted: 9 June 2021
First Online: 11 July 2021
Declarations
:
: PH: received research funding, consultancy, and lecture fees from Amgen Inc., AstraZeneca, Eli Lilly, Gedeon Richter, Mylan, Novartis, Pfizer, and UCB Pharma. BS: Employee of ICON (formerly Mapi); paid consultant for this study. EK: former employee of Vilua Healthcare GmbH (formerly Arvato Health Analytics GmbH), which received funding from UCB Pharma and Mapi (now ICON) to perform the analyses. PG, LJ, ET: UCB Pharma employees. LM: former UCB Pharma employee that has received consultancy and lecture fees from UCB Pharma. CCG: received research funding, consultancy, and lecture fees from Amgen Inc., Eli Lilly, Novartis, and UCB Pharma.